Page 179 - 磁共振成像2024年7期电子刊

综 述｜｜Reviews 磁共振成像 2024年7月第15卷第7期 Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7

23685. [63] JIANG S, GUO P, HEO H Y, et al. Radiomics analysis of amide proton
[49] FU J, SINGHRAO K, ZHONG X R, et al. An automatic deep transfer-weighted and structural MR images for treatment response
learning-based workflow for glioblastoma survival prediction using assessment in malignant gliomas[J/OL]. NMR Biomed, 2023, 36(1):
preoperative multimodal MR images: A feasibility study[J/OL]. Adv e4824 [2024-03-04]. https://pubmed. ncbi. nlm. nih. gov/36057449/. DOI:
Radiat Oncol, 2021, 6(5): 100746 [2024-03-04]. https://pubmed.ncbi.nlm. 10.1002/nbm.4824.
nih.gov/34458648/. DOI: 10.1016/j.adro.2021.100746. [64] ZHANG J, WU Y, WANG Y, et al. Diffusion-weighted imaging and
[50] NIE D, LU J, ZHANG H, et al. Multi‐channel 3D deep feature learning arterial spin labeling radiomics features may improve differentiation
for survival time prediction of brain tumor patients using multi‐modal between radiation-induced brain injury and glioma recurrence[J]. Eur
neuroimages[J/OL]. Sci Rep, 2019, 9(1): 1103 [2024-03-04]. https:// Radiol, 2023, 33(5): 3332-3342. DOI: 10.1007/s00330-022-09365-3.
pubmed.ncbi.nlm.nih.gov/30705340/. DOI: 10.1038/s41598-018-37387-9. [65] REN J F, ZHAI X Y, YIN H J. Multimodality MRI radiomics based on
[51] TANG Z, XU Y, JIN L, et al. Deep learning of imaging phenotype and machine learning for identifying true tumor recurrence and treatment-related
genotype for predicting overall survival time of glioblastoma patients[J]. effects in patients with postoperative glioma[J]. Neurol Ther, 2023, 12(5):
IEEE Trans Med Imaging, 2020, 39(6): 2100-2109. DOI: 10.1109/ 1729-1743. DOI: 10.1007/s40120-023-00524-2.
TMI.2020.2964310. [66] MANA M, SHAHRIAR F, GIAN M C, et al. A deep learning model for
[52] CHAE J P, KYUNGHWA H, HWIYOUNG K, et al. Radiomics risk discriminating true progression from pseudoprogression in glioblastoma
score may be a potential imaging biomarker for predicting survival in patients[J]. J Neurooncol, 2022, 159(2): 447-455. DOI: 10.1007/s11060-
isocitrate dehydrogenase wild-type lower-grade gliomas[J]. Eur Radiol, 022-04080-x.
2020, 30(12): 6464-6474. DOI: 10.1007/s00330-020-07089-w. [67] CHOI S, YU Y, GRIMMER M R, et al. Temozolomide-associated
[53] VERDUGO E, PUERTO I, MEDINA M Á. An update on the molecular hypermutation in gliomas[J]. Neuro Oncol, 2018, 20(10): 1300-1309.
biology of glioblastoma, with clinical implications and progress in its DOI: 10.1093/neuonc/noy016.
treatment[J]. Cancer Commun, 2022, 42(11): 1083-1111. DOI: 10.1002/ [68] CRAIG H, LOUIS B N, JANA P, et al. NCCN guidelines(R) insights:
cac2.12361. central nervous system cancers, version 2.2022[J]. J Natl Compr Canc
[54] MALMSTRÖM A, ŁYSIAK M, ÅKESSON L, et al. ABCB1 Netw, 2023, 21(1): 12-20. DOI: 10.6004/jnccn.2023.0002.
single-nucleotide variants and survival in patients with glioblastoma treated [69] GRAMATZKI D, ROTH P, RUSHING E J, et al. Bevacizumab may
with radiotherapy concomitant with temozolomide[J]. Pharmacogenomics J, improve quality of life, but not overall survival in glioblastoma: an
2020, 20(2): 213-219. DOI: 10.1038/s41397-019-0107-z. epidemiological study[J]. Ann Oncol, 2018, 29(6): 1431-1436. DOI:
[55] KELLY C, MAJEWSKA P, IOANNIDIS S, et al. Estimating 10.1093/annonc/mdy106.
progression-free survival in patients with glioblastoma using routinely [70] LI Y R, XU W L, FEI Y L, et al. A MRI-based radiomics model for
collected data[J]. J Neurooncol, 2017, 135(3): 621-627. DOI: 10.1007/ predicting the response to anlotinb combined with temozolomide in
s11060-017-2619-1. recurrent malignant glioma patients[J/OL]. Discov Oncol, 2023, 23,
[56] DAYTON G, DAVID P, MEGAN C, et al. Clinical and radiographic 14(1): 154 [2024-03-04]. https://pubmed.ncbi.nlm.nih.gov/37612579/.
characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular DOI: 10.1007/s12672-023-00751-x.
features of glioblastoma: a single institution review[J]. J Neurooncol, 2022, [71] WEI J W, YANG G G, HAO X H, et al. A multi-sequence and
157(1): 187-195. DOI: 10.1007/s11060-022-03961-5. habitat-based MRI radiomics signature for preoperative prediction of
[57] PARK C J, HAN K, KIM H, et al. MRI features may predict molecular MGMT promoter methylation in astrocytomas with prognostic
features of glioblastoma in isocitrate dehydrogenase wild-type lower-grade implication[J]. Eur Radiol, 2019, 29(2): 877-888. DOI: 10.1007/
gliomas[J]. AJNR Am J Neuroradiol, 2021, 42(3): 448-456. DOI: 10.3174/ s00330-018-5575-z.
ajnr.A6983. [72] BOBHOLZ S A, HOEFS A, HAMBURGER J, et al. Radio-pathomic
[58] XIN K, YU M, YU Q L, et al. Machine learning models based on maps of glioblastoma identify phenotypes of non-enhancing tumor
multi-parameter MRI radiomics for prediction of molecular infiltration associated with bevacizumab treatment response[J]. J
glioblastoma: a new study based on the 2021 World Health Organization Neurooncol, 2024, 167(2): 233-241. DOI: 10.1007/s11060-024-04593-7.
classification[J]. Acta Radiol, 2023, 64(11): 2938-2947. DOI: 10.1177/ [73] WANG H, XU T, HUANG Q, et al. Immunotherapy for malignant
02841851231199744. glioma: Current status and future directions[J]. Trends Pharmacol Sci,
[59] YAE W P, SOOYON K, CHAE J, et al. Adding radiomics to the 2021 2020, 41(2): 123-138. DOI: 10.1016/j.tips.2019.12.003.
WHO updates may improve prognostic prediction for current [74] KE Y Y, ZHI J W, HAO Z, et al. Glioma targeted therapy: insight into
IDH-wildtype histological lower-grade gliomas with known EGFR future of molecular approaches[J/OL]. Mol Cancer, 2022, 21(1): 39
amplification and TERT promoter mutation status[J]. Eur Radiol, 2022, [2024-03-04]. https://pubmed.ncbi.nlm.nih.gov/35135556/. DOI: 10.1186/
32(12): 8089-8098. DOI: 10.1007/s00330-022-08941-x. s12943-022-01513-z.
[60] FUJIMOTO K, ARITA H, SATOMI K, et al. TERT promoter mutation [75] DAPASH M, HOU D, CASTRO B, et al. The interplay between
status is necessary and sufficient to diagnose IDH-wildtype diffuse glioblastoma and its microenvironment[J/OL]. Cells, 2021, 10(9): 2257
astrocytic glioma with molecular features of glioblastoma[J]. Acta [2024-03-04]. https://pubmed.ncbi.nlm.nih.gov/34571905/. DOI: 10.3390/
Neuropathol, 2021, 142(2): 323-338. DOI: 10.1007/s00401-021-02337-9. cells10092257.
[61] DU P, WU X F, LIU X, et al. Establishment of a prediction model based [76] CHEN D, ZHANG R, HUANG X, et al. MRI-derived radiomics
on preoperative MRI radiomics for diffuse astrocytic glioma, assessing tumor-infiltrating macrophages enable prediction of
IDH-wildtype, with molecular features of glioblastoma[J/OL]. Cancers immune-phenotype, immunotherapy response and survival in glioma[J/OL].
(Basel), 2023, 15(20): 5094 [2024-03-04]. https://pubmed.ncbi.nlm.nih. Biomark Res, 2024, 12(1): 14 [2024-03-04]. https://pubmed.ncbi.nlm.
gov/37894461/. DOI: 10.3390/cancers15205094. nih.gov/38291499/. DOI: 10.1186/s40364-024-00560-6.
[62] PARK Y W, CHOI D, PARK J E, et al. Differentiation of recurrent [77] LUAN J, ZHANG D, LIU B, et al. Immune-related lncRNAs signature
gli-oblastoma from radiation necrosis using diffusion radiomics with and radiomics signature predict the prognosis and immune
machine learning model development and external validation[J/OL]. microenvironment of glioblastoma multiforme[J/OL]. J Transl Med, 2024,
Sci Rep, 2021, 11(1): 2913 [2024-03-04]. https://pubmed.ncbi.nlm.nih. 22(1): 107 [2024-03-04]. https://pubmed.ncbi.nlm.nih.gov/38279111/.
gov/33536499/. DOI: 10.1038/s41598-021-82467-y. DOI: 10.1186/s12967-023-04823-y.

·172 · https://www.chinesemri.com